English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

equally be used for therapeutic drug monitoring of biosimilars of infliximab J. Afonso1,2, H.T. Sousa3, I.Rosa4, J.Carvalho5, C. C. Dias6,7 F. Magro1,2,8 on behalf GEDII 1Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal; 2MedInUP, Centre for Drug Discovery and Innovative Medicines, University of Porto, 4200 Porto, Portugal; 3Gastroenterology Department, Centro Hospitalar do Algarve, Portimão, Portugal; 4Gastroenterology Department, Instituto Português de Oncologia de Lisboa, Lisboa, Portugal; 5Department of Gastroenterology and Hepatology, Centro Hospitalar de Gaia, Gaia, Portugal; 6Health Information and Decision Sciences Department, Faculty of Medicine, University of Porto, Porto, Portugal; 7Center for Health Technology and Services Research, Porto, Portugal; 8Gastroenterology Department, Centro Hospitalar São João, Porto

P248 The new infliximab point-of-care quantitative test can equally be used for therapeutic drug monitoring of biosimilars of infliximab